Aquestive Therapeutics, Inc.(AQST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,864 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AQST Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Aquestive Therapeutics, Inc. (AQST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AQST at 14.5/100 on a 32-signal composite quality model, placing it at rank #2,864 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (2.3) and profitability (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Aquestive Therapeutics, Inc. reports quarterly revenue of $13.8M, net income of $-22.9M, free cash flow of $-9.7M. Top institutional holders of AQST by reported 13-F value include Bratton Capital Management, L.P., BlackRock, RTW INVESTMENTS, based on the most recent SEC filings. AQST trades on the Nasdaq exchange and files with the SEC under CIK 1398733. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AQST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aquestive Therapeutics, Inc. directly from SEC EDGAR. Aquestive Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 27 since 2021, currently 14.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$13.8M
Net Income
Q2 2026
$-22.9M
Free Cash Flow
Q2 2026
$-9.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-22.6% YoYNet Income
-89.8% YoYOperating Income
-130.9% YoYEPS (Diluted)
-52.9% YoYTotal Assets
+58.2% YoYTotal Debt
+22.2% YoYOp. Cash Flow
-46.6% YoYFree Cash Flow
-47.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $44.5M -22.6% | $57.6M +13.8% | $50.6M +6.1% | $47.7M -6.2% | $50.8M +10.9% | $45.8M |
| Net Income | $-83.8M -89.8% | $-44.1M -460.8% | $-7.9M +85.5% | $-54.4M +22.9% | $-70.5M -26.5% | $-55.8M |
| Operating Income | $-71.1M -130.9% | $-30.8M -103.8% | $-15.1M +64.1% | $-42.1M -21.3% | $-34.7M +19.1% | $-42.9M |
| EPS (Diluted) | $-0.78 -52.9% | $-0.51 -292.3% | $-0.13 +88.4% | $-1.12 +39.5% | $-1.85 -11.4% | $-1.66 |
| Total Assets | $160.4M +58.2% | $101.4M +76.6% | $57.4M +0.6% | $57.1M -7.9% | $62.0M -1.4% | $62.9M |
| Total Debt | $55.0M +22.2% | $45.0M +0.0% | $45.0M +34.5% | $33.4M | — | $51.5M |
| Operating Cash Flow | $-52.4M -46.6% | $-35.8M -460.5% | $-6.4M +35.0% | $-9.8M +70.2% | $-33.0M +27.5% | $-45.5M |
| Free Cash Flow | $-53.0M -47.5% | $-35.9M -387.0% | $-7.4M +32.0% | $-10.8M +68.0% | $-33.9M +26.3% | $-46.0M |
Get alerted when AQST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aquestive Therapeutics, Inc. including:
Top Institutional Holders of AQST
Bratton Capital Management, L.P.
$40.8M9,810,958 shBlackRock, Inc.
$33.6M8,069,373 shRTW INVESTMENTS, LP
$30.9M7,426,471 shVANGUARD CAPITAL MANAGEMENT LLC
$19.1M4,584,533 shFEDERATED HERMES, INC.
$12.9M3,112,561 shSTATE STREET CORP
$12.2M2,928,020 shGEODE CAPITAL MANAGEMENT, LLC
$10.9M2,622,888 shSamsara BioCapital, LLC
$10.4M2,500,000 shBANK OF AMERICA CORP /DE/
$6.9M1,668,423 shSio Capital Management, LLC
$6.2M1,486,175 sh
| Fund | Value | Shares |
|---|---|---|
| Bratton Capital Management, L.P. | $40.8M | 9,810,958 |
| BlackRock, Inc. | $33.6M | 8,069,373 |
| RTW INVESTMENTS, LP | $30.9M | 7,426,471 |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.1M | 4,584,533 |
| FEDERATED HERMES, INC. | $12.9M | 3,112,561 |
| STATE STREET CORP | $12.2M | 2,928,020 |
| GEODE CAPITAL MANAGEMENT, LLC | $10.9M | 2,622,888 |
| Samsara BioCapital, LLC | $10.4M | 2,500,000 |
| BANK OF AMERICA CORP /DE/ | $6.9M | 1,668,423 |
| Sio Capital Management, LLC | $6.2M | 1,486,175 |
Companies Similar to AQST
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Silence Therapeutics plc
Pelthos Therapeutics Inc.
OCULAR THERAPEUTIX, INC
Arcus Biosciences, Inc.
ALUMIS INC.
Wave Life Sciences, Inc.
Zymeworks Inc.
Upstream Bio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AQST on your watchlist
Track score changes the day Aquestive Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AQST a good stock to buy?
13F Pro's AI-powered analysis of Aquestive Therapeutics, Inc. (AQST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AQST are available on the AQST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AQST is classified as a small company.
Which hedge funds own AQST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AQST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aquestive Therapeutics, Inc.'s investment landscape.